SCHEMBL666124

SCHEMBL666124

CC(C)(C)OC(=O)N1CCC(c2ccc(F)nc2)CC1

nearest known ligand 0.60

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 1/20 0.60
CRBN Q96SW2 1/20 0.60
NAMPT P43490 1/20 0.52
WNT3A P56704 1/20 0.51
GPR119 Q8TDV5 8/20 0.49
KDM4E B2RXH2 1/20 0.48
MAPT P10636 1/20 0.48
THRB P10828 1/20 0.48
POLB P06746 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
HPGDS O60760 1/20 0.47
P2RY14 Q15391 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21504577 0.93 PDE4B (0.53) DDB1CRBNNAMPTWNT3AGPR119
SCHEMBL30395072 0.87 DDB1 (0.46) DDB1CRBNNAMPTGPR119KDM4E
SCHEMBL20757383 0.87 DDB1 (0.46) DDB1CRBNNAMPTGPR119KDM4E
SCHEMBL24837748 0.87 DDB1 (0.55) DDB1CRBNNAMPTWNT3AGPR119
SCHEMBL25598233 0.85 DDB1 (0.58) DDB1CRBNNAMPTWNT3AGPR119
SCHEMBL31737074 0.85 DDB1 (0.60) DDB1CRBNNAMPTWNT3AGPR119
SCHEMBL25931442 0.85 DDB1 (0.60) DDB1CRBNNAMPTWNT3AGPR119
SCHEMBL29497122 0.85 DDB1 (0.60) DDB1CRBNNAMPTWNT3AGPR119
SCHEMBL611718 0.85 DDB1 (0.60) DDB1CRBNNAMPTWNT3AGPR119
SCHEMBL10180063 0.84 GPR119 (0.59) DDB1CRBNNAMPTWNT3AGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107759563-B Preparation method of 4- (6-substituted aminopyridine-3-yl) piperidine-1-tert-butyl formate 上海再启生物技术有限公司 2020-06-02 CN claimed
CN-107759563-B Preparation method of 4- (6-substituted aminopyridine-3-yl) piperidine-1-tert-butyl formate 上海再启生物技术有限公司 2020-06-02 CN disclosed
US-9040560-B2 Amino azaheterocyclic carboxamides MERCK PATENT GMBH (DE) 2015-05-26 US disclosed
EP-2396307-B1 NOVEL AMINO AZAHETEROCYCLIC CARBOXAMIDES MERCK PATENT GMBH (DE) 2014-10-15 EP disclosed
US-20140107156-A1 Novel Amino Azaheterocyclic Carboxamides MERCK PATENT GMBH (DE) 2014-04-17 US disclosed
US-8637532-B2 Amino azaheterocyclic carboxamides MERCK PATENT GMBH (DE) 2014-01-28 US disclosed
US-20120046269-A1 Novel Amino Azaheterocyclic Carboxamides MERCK PATENT GMBH (DE) 2012-02-23 US disclosed
US-7727998-B2 Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-06-01 US disclosed
US-20060106046-A1 Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient MSD K.K. (JP) 2006-05-18 US disclosed
EP-1595867-A1 MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS CONTAINING PIPERIDINE DERIVATIVES AS THE ACTIVE INGREDIENT BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-11-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140107156-A1 Novel Amino Azaheterocyclic Carboxamides AZI2, MKI67, MYC DDB1 310/4885CRBN 642/4885NAMPT 673/4885
US-20120046269-A1 Novel Amino Azaheterocyclic Carboxamides AZI2, MKI67, MYC DDB1 310/4885CRBN 642/4885NAMPT 673/4885
US-20060106046-A1 Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient MCHR1, MC1R, PRLHR DDB1 4409/4885CRBN 2132/4885NAMPT 4212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.